Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results.

@article{Shields2014IntravitrealMF,
  title={Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results.},
  author={Carol L. Shields and Fairooz P Manjandavida and Sruthi Arepalli and Swathi Kaliki and Sara E. Lally and Jerry A. Shields},
  journal={JAMA ophthalmology},
  year={2014},
  volume={132 3},
  pages={
          319-25
        }
}
IMPORTANCE Recurrent or persistent vitreous seeds following treatment of retinoblastoma poses difficult management and often leads to enucleation. OBJECTIVE To describe the technique and evaluate the efficacy and complications of intravitreal melphalan for vitreous seeding from retinoblastoma. DESIGN, SETTING, AND PARTICIPANTS This retrospective noncomparative analysis was conducted at a tertiary referral center. The study included 11 consecutive eyes of 11 patients with viable persistent… Expand

Paper Mentions

Interventional Clinical Trial
Over the past 15 years, intravenous chemotherapy has become the most popular conservative (eye-saving) method for retinoblastoma treatment because it is often effective and usually… Expand
ConditionsRetinoblastoma
InterventionDrug
Outcomes of intravitreal melphalan for vitreous seedings in retinoblastoma resistant to systemic chemotherapy
TLDR
Intravitreal injection melphalan shows promising results in the treatment of vitreous seeds in retinoblastoma, resistant to systemic chemotherapy. Expand
Intravitreal Melphalan Chemotherapy for Vitreous Seeds in Retinoblastoma
TLDR
Intravitrealmelphalan is a promising modality for treatment of vitreous seeds, and the dose of 20–30 μg of melphalan sounds to be safe and effective for refractory and recurrent vitreOUS seeds. Expand
Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma.
TLDR
Administration of combined intravitreal melphalan and topotecan in eyes not subsequently enucleated appears to be safe and effective for resistant or recurrent vitreous seeds from retinoblastoma. Expand
Safety and Efficacy of Intravitreal Chemotherapy (Melphalan) to Treat Vitreous Seeds in Retinoblastoma
TLDR
IViC with melphalan is effective (more for focal than diffuse seeding) and a relatively safe treatment modality for Rb that can improve the outcomes of eye salvage procedures, however, unexpected toxicity can occur even with the standard dose of 20–30 μg. Expand
INTRAVITREOUS CHEMOTHERAPY FOR ACTIVE VITREOUS SEEDING FROM RETINOBLASTOMA: Outcomes After 192 Consecutive Injections. The 2015 Howard Naquin Lecture
TLDR
Intravitreal melphalan and/or topotecan injection for retinoblastoma vitreous seeding provides lasting tumor control at 3 years with approximately 4 injections. Expand
Intravitreal topotecan in the management of refractory and recurrent vitreous seeds in retinoblastoma
TLDR
Three-weekly intravitreal topotecan appears effective and safe in controlling focal or diffuse refractory or recurrent vitreous seeds in retinoblastoma. Expand
Intravitreal Chemotherapy in the Management of Vitreous Disease in Retinoblastoma
TLDR
Intravitreal melphalan at 30-40 µg in 1 or 2 injections proved effective in 69.2% of eyes with vitreous disease and Vitreous hemorrhage and retinal pigment epithelial alterations were the most common side effects. Expand
Intravitreal Lower-Dose (20 µg) Melphalan for Persistent or Recurrent Retinoblastoma Vitreous Seeds.
TLDR
The 2-year results of this study suggest that standard lower-dose (20 µg) intravitreal melphalan is safe and highly effective for the management of viable VS from retinoblastoma. Expand
Ocular toxicity of intravitreal melphalan for retinoblastoma in Chinese patients
TLDR
Intravitreal melphalan is an effective treatment for refractory vitreous seeding from retinoblastoma, but exhibits both anterior and posterior segment toxicity in Chinese patients. Expand
Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol
  • A. Solana-Altabella, S. Valero, +5 authors J. Poveda
  • Medicine
  • Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • 2020
TLDR
A new intravitreal chemotherapy retinoblastoma treatment protocol for children implanting vitreous seeds through intrav itreal melphalan injections is described and the patients’ health outcomes treated with it is evaluated. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 28 REFERENCES
Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications
TLDR
Despite a possible confounding effect of concomitant chemotherapy prescription using other routes of administration in four of the successfully treated eyes, IViC achieved an unprecedented success rate of tumour control in the presence of vitreous seeding. Expand
Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma.
TLDR
Intravitreal melphalan for recurrent vitreous seeds from retinoblastoma appears to provide vitreOUS seed control in some patients, and a high dose (50 μg) ofmelphalan is toxic and should be avoided. Expand
Combined intravitreal and subconjunctival carboplatin for retinoblastoma with vitreous seeds
TLDR
Injecting a bleb of subconjunctival chemotherapy prior to intravitreal drug delivery appeared to mitigate the risk of orbital tumour seeding in two patients with advanced stage retinoblastoma. Expand
Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track
TLDR
This technique is potentially safe and effective at a low cost and may play a promising role, especially in the treatment of recurrent and/or resistant vitreous disease in retinoblastoma, as an alternative to enucleation and/ or external beam radiotherapy. Expand
Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds.
TLDR
Tumor control following intra-arterial chemotherapy (IAC) for retinoblastoma is described and globe salvage was achieved in 8 of 12 eyes treated with primary IAC, including 2 of 2 group C eyes, 4 of 4 group D eyes, and 2 of 6 group E eyes according to the International Classification of Retin Oblastoma. Expand
Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma.
TLDR
Chemoreduction combined with focal therapy is effective for selected eyes with retinoblastomas and eyes with subretinal seeds at initial examination are at particular risk for recurrence of retinal tumor and vitreous seeds. Expand
Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience.
TLDR
The authors' experience suggests that intra-arterial chemotherapy is safe and effective in the treatment of advanced intraocular retinoblastoma. Expand
MANAGEMENT OF ADVANCED RETINOBLASTOMA WITH INTRAVENOUS CHEMOTHERAPY THEN INTRA-ARTERIAL CHEMOTHERAPY AS ALTERNATIVE TO ENUCLEATION
TLDR
After primary IVC plus secondary IAC, globe salvage was achieved in 8 patients (57%) at mean 2-year follow-up and there was no evidence of retinoblastoma metastasis or death and no sign of second cancer or life-threatening complication. Expand
Eye-preservation treatment of retinoblastoma with vitreous seeding.
TLDR
Catastrophic retinoblastoma with vitreous seeding has been one of the most challenging conditions for eye-preservation therapy, and chemotherapy has become the most promising method to cure not only recurrence but also primary tumors. Expand
Intravitreal chemotherapy for recurrent retinoblastoma in an only eye.
TLDR
Regional anaesthesia for 12 000 cataract extraction and intraocular lens implantation procedures and Simulated peribulbar injection of anaesthetic. Expand
...
1
2
3
...